FDA updates Ozempic label with potential blocked intestines side effect, also reported with Wegovy and Mounjaro
CBSN
The label for the diabetes drug Ozempic — which has become popular for weight loss — now acknowledges reports of blocked intestines following use of the medication. The change comes after the Food and Drug Administration greenlighted a series of updates from drugmaker Novo Nordisk for its product.
Ozempic now joins other products in this booming class of so-called GLP-1 agonist medications which acknowledge increased reports of what doctos call ileus, or a blockage in the intestines.
Weight loss drug Wegovy, which is also an injection of semaglutide manufactured by Novo Nordisk, acknowledges reports of ileus on its label as well, as does Mounjaro, a diabetes medication from Eli Lilly.
A class of drugs known as GLP-1s have been helping people lose weight, but out of pocket costs put them out of reach for many Americans. In West Virginia, a subsidy program for public employees was showing promising results, but then the state abruptly ended it, leaving many searching for new solutions.